Skip to main content
Top
Published in: Respiratory Research 1/2023

Open Access 01-12-2023 | Expectoration | Research

Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples

Authors: Cecilia Brettoni, Alessandro Muzzi, Simona Rondini, Vincent Weynants, Silvia Rossi Paccani

Published in: Respiratory Research | Issue 1/2023

Login to get access

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a lung disease characterised by airflow-limiting inflammation and mucus production. Acute exacerbations are a major cause of COPD-related morbidity and mortality and are mostly associated with bacterial or viral infections. A vaccine targeting non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat), the main bacteria associated with exacerbations, was tested in a Phase 2 trial. We assessed “ex-vivo” expression of vaccine candidate and housekeeping genes pd, pe, pilA, gapA, ompP6 of NTHi, and uspA2, parE, polA of Mcat in sputum samples of COPD patients and determined whether expression of the vaccine candidate genes pd, pe, pilA (NTHi) and uspA2 (Mcat) differed between stable and exacerbation samples.

Methods

A single-centre, prospective, observational cohort study was conducted where 123 COPD patients were seen on enrolment, followed monthly for 2 years, and reviewed after onset of acute exacerbations. We selected 69 patients with sputum samples positive for NTHi or Mcat by PCR during at least one stable and one exacerbation visit. mRNA was isolated from the sputum, and expression of NTHi and Mcat genes was analysed with RT-PCR. Statistical analyses compared mRNA concentrations between stable and exacerbation samples and in relationship to COPD severity and exacerbation frequency.

Results

The vaccine candidate genes were variably expressed in sputum samples, suggesting they are expressed in the lung. Absolute and relative expression of all NTHi vaccine candidate genes and Mcat uspA2 were similar between exacerbation and stable samples. Expression of pd and pilA was slightly associated with the number of exacerbations in the year before enrolment, and uspA2 with the disease severity status at enrolment.

Conclusions

The NTHi-Mcat vaccine candidate genes were expressed in sputum samples, and each gene had a specific level of expression. No statistically significant differences in gene expression were detectable between stable and exacerbation samples. However, the history of COPD exacerbations was slightly associated with the expression of pd, pilA and uspA2.
Trial registration NCT01360398 (https://​www.​clinicaltrials.​gov)

Graphical abstract

Appendix
Available only for authorised users
Literature
3.
go back to reference Gibson G, Loddenkemper R, Lundback B, Sibille Y, editors. European lung white book. Respiratory health and disease in Europe. 2nd ed. Sheffield: European Respiratory Society; 2013. Gibson G, Loddenkemper R, Lundback B, Sibille Y, editors. European lung white book. Respiratory health and disease in Europe. 2nd ed. Sheffield: European Respiratory Society; 2013.
4.
go back to reference Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387–95.CrossRefPubMedPubMedCentral Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387–95.CrossRefPubMedPubMedCentral
5.
go back to reference Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.CrossRefPubMedPubMedCentral Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.CrossRefPubMedPubMedCentral
6.
go back to reference Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139–47.CrossRefPubMed Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139–47.CrossRefPubMed
7.
go back to reference Nishimura K, Sato S, Tsukino M, Hajiro T, Ikeda A, Koyama H, et al. Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2009;7:69.CrossRefPubMedPubMedCentral Nishimura K, Sato S, Tsukino M, Hajiro T, Ikeda A, Koyama H, et al. Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2009;7:69.CrossRefPubMedPubMedCentral
8.
go back to reference Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355–65.CrossRefPubMed Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355–65.CrossRefPubMed
9.
go back to reference Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, et al. Safety and immunogenicity of non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine. Vaccine. 2019;37:3113–22.CrossRefPubMed Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, et al. Safety and immunogenicity of non-typeable Haemophilus influenzaeMoraxella catarrhalis vaccine. Vaccine. 2019;37:3113–22.CrossRefPubMed
10.
go back to reference Bourne S, Cohet C, Kim V, Barton A, Tuck A, Aris E, et al. Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study. BMJ Open. 2014;4: e004546.CrossRefPubMedPubMedCentral Bourne S, Cohet C, Kim V, Barton A, Tuck A, Aris E, et al. Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study. BMJ Open. 2014;4: e004546.CrossRefPubMedPubMedCentral
12.
go back to reference Wilkinson TMA, Aris E, Bourne S, Clarke SC, Peeters M, Pascal TG, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72:919–27.CrossRefPubMed Wilkinson TMA, Aris E, Bourne S, Clarke SC, Peeters M, Pascal TG, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72:919–27.CrossRefPubMed
13.
go back to reference Malvisi L, Taddei L, Yarraguntla A, Wilkinson TMA, Arora AK, on behalf of the AERIS Study Group. Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints. Respir Res. 2021;22:67.CrossRefPubMedPubMedCentral Malvisi L, Taddei L, Yarraguntla A, Wilkinson TMA, Arora AK, on behalf of the AERIS Study Group. Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints. Respir Res. 2021;22:67.CrossRefPubMedPubMedCentral
14.
go back to reference Riedel G, Rudrich U, Fekete-Drimusz N, Manns MP, Vondran FW, Bock M. An extended ΔCT-method facilitating normalisation with multiple reference genes suited for quantitative RT-PCR analyses of human hepatocyte-like cells. PLoS ONE. 2014;9: e93031.CrossRefPubMedPubMedCentral Riedel G, Rudrich U, Fekete-Drimusz N, Manns MP, Vondran FW, Bock M. An extended ΔCT-method facilitating normalisation with multiple reference genes suited for quantitative RT-PCR analyses of human hepatocyte-like cells. PLoS ONE. 2014;9: e93031.CrossRefPubMedPubMedCentral
15.
go back to reference Moermans C, Deliege E, Pirottin D, Poulet C, Guiot J, Henket M, et al. Suitable reference genes determination for real-time PCR using induced sputum samples. Eur Respir J. 2019;54:1800644.CrossRefPubMed Moermans C, Deliege E, Pirottin D, Poulet C, Guiot J, Henket M, et al. Suitable reference genes determination for real-time PCR using induced sputum samples. Eur Respir J. 2019;54:1800644.CrossRefPubMed
16.
go back to reference Boixeda R, Almagro P, Diez-Manglano J, Cabrera FJ, Recio J, Martin-Garrido I, et al. Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2581–91.CrossRefPubMedPubMedCentral Boixeda R, Almagro P, Diez-Manglano J, Cabrera FJ, Recio J, Martin-Garrido I, et al. Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2581–91.CrossRefPubMedPubMedCentral
17.
go back to reference Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73:422–30.CrossRefPubMed Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73:422–30.CrossRefPubMed
18.
go back to reference Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. 2016;47:1082–92.CrossRefPubMed Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. 2016;47:1082–92.CrossRefPubMed
19.
go back to reference Galiana A, Aguirre E, Rodriguez JC, Mira A, Santibanez M, Candela I, et al. Sputum microbiota in moderate versus severe patients with COPD. Eur Respir J. 2014;43:1787–90.CrossRefPubMed Galiana A, Aguirre E, Rodriguez JC, Mira A, Santibanez M, Candela I, et al. Sputum microbiota in moderate versus severe patients with COPD. Eur Respir J. 2014;43:1787–90.CrossRefPubMed
20.
go back to reference Garcia-Nunez M, Millares L, Pomares X, Ferrari R, Perez-Brocal V, Gallego M, et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52:4217–23.CrossRefPubMedPubMedCentral Garcia-Nunez M, Millares L, Pomares X, Ferrari R, Perez-Brocal V, Gallego M, et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52:4217–23.CrossRefPubMedPubMedCentral
Metadata
Title
Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples
Authors
Cecilia Brettoni
Alessandro Muzzi
Simona Rondini
Vincent Weynants
Silvia Rossi Paccani
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2023
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-023-02525-z

Other articles of this Issue 1/2023

Respiratory Research 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine